PRESS RELEASES
- October 13, 2011
Horizon Pharma Receives U.S. Patent Allowance for DUEXIS in the United States - September 06, 2011
Horizon Pharma Receives U.S. Patent Allowance for DUEXIS® (ibuprofen/famotidine) - August 31, 2011
Horizon Pharma Reports Second Quarter 2011 Financial Results - August 25, 2011
Horizon Pharma to Present at the 2011 Stifel Nicolaus Healthcare Conference - July 28, 2011
Horizon Pharma Announces Pricing of its Initial Public Offering - April 25, 2011
Horizon Pharma Announces FDA Approval of DUEXIS®(ibuprofen/famotidine) for the Relief of the Signs and Symptoms of Rheumatoid Arthritis and Osteoarthritis and to Decrease the Risk of Developing Upper Gastrointestinal Ulcers - November 09, 2010
Horizon Pharma Presents HZT-501 Long-Term Safety Data and LODOTRA® Phase 3 Data at the American College of Rheumatology Annual Meeting - November 08, 2010
Horizon Pharma Awarded Therapeutic Discovery Grant - November 05, 2010
Horizon Pharma, Inc Provides Update on November 4, 2010 FDA Gastrointestinal Drugs Advisory Committee Meeting - November 05, 2010
Horizon Pharma Enters into Exclusive Agreement with Mundipharma for Commercialization of LODOTRA® (Modified-Release Prednisone) in Asia - November 02, 2010
Horizon Pharma Announces HZT-501 and LODOTRA® (Modified-Release Prednisone) Data to be Presented at the American College of Rheumatology Annual Meeting - August 03, 2010
Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering - July 23, 2010
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis - June 16, 2010
Horizon Pharma, Inc. Presents Results of Phase 3 Studies of LODOTRA® Demonstrating Statistically Significant Improvement in Response in Rheumatoid Arthritis Patients - June 09, 2010
Horizon Pharma Announces LODOTRA® and HZT-501 Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress - May 26, 2010
Horizon Pharma, Inc. Announces FDA Acceptance of HZT-501 New Drug Application for Filing - May 19, 2010
Horizon Pharma, Inc. Presents Interim Results from a Pilot Clinical Study Evaluating LODOTRA® in the Treatment of Severe Nocturnal Asthma - April 01, 2010
Horizon Therapeutics and Nitec Pharma Complete Merger and Combine Businesses - March 15, 2010
Pain Meds Can Cause Serious Side Effects. - October 26, 2009
Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users - October 21, 2009
AGA Institute and Horizon Therapeutics Expand CONNECT to Protect Program to Educate Consumers on NSAID Risk - June 29, 2009
Horizon Therapeutics Names Dr. Jeffery W. Sherman Executive Vice President and Chief Medical Officer - June 01, 2009
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients with Mild-to-Moderate Pain - June 01, 2009
AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated with NSAID Use - April 14, 2009
Nitec Announces First Launch of LODOTRA® In Germany - March 31, 2009
Nitec Pharma Grants Exclusive European Distribution License to MundiPharma for LODOTRA™ - March 23, 2009
Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California - February 27, 2009
Nitec Pharma Completes Recruitment on US Phase III Trial for LODOTRA™ - January 07, 2009
Nitec Pharma's New Rheumatoid Arthritis Treatment,LODOTRA™, Recommended for European Regulatory Approval - January 06, 2009
Horizon Therapeutics Announces Senior Management Appointments - December 02, 2008
Horizon Therapeutics Announces Two Pivitol HZT-501 Phase 3 Trials Meet Primary Endpoints - October 09, 2008
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer - October 01, 2008
Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference - September 19, 2008
Horizon Therapeutics to Present at UBS Global Life Sciences Conference - July 31, 2008
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area - July 24, 2008
Horizon Therapeutics Names Timothy P. Walbert as President and CEO - February 11, 2008
Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501 - October 08, 2007
Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 - July 23, 2007
Horizon Therapeutics Completes $30 Million Equity Financing to Advance Pipeline of 'GI-Friendly' NSAIDs for Mild to Moderate Pain - March 27, 2007
Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials for 'GI-Friendly' NSAID - January 08, 2007
Horizon Therapeutics Announces Special Protocol Assessment with FDA for Phase 3 Trial Program - January 04, 2007
Horizon Therapeutics completes $21 million in equity financing to advance pipeline of 'GI-friendly' NSAIDs for mild-to-moderate pain